DESOXY

Last updated
DESOXY
DESOXY.png
DESOXY-3d-sticks.png
Clinical data
Other names4-Methyl-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-methylphenethylamine
Routes of
administration 		Oral [1]
Drug class Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action 6–8 hours [1]
Identifiers
  • 2-(3,5-dimethoxy-4-methylphenyl)ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C11H17NO2
Molar mass 195.262 g·mol−1
3D model (JSmol)
  • Cc1c(cc(cc1OC)CCN)OC
  • InChI=1S/C11H17NO2/c1-8-10(13-2)6-9(4-5-12)7-11(8)14-3/h6-7H,4-5,12H2,1-3H3 Yes check.svgY
  • Key:LLHRMWHYJGLIEV-UHFFFAOYSA-N Yes check.svgY
   (verify)

4-Desoxymescaline, or 4-methyl-3,5-dimethoxyphenethylamine, is a mescaline analogue related to other psychedelic phenethylamines. [2] It is commonly referred to as DESOXY. [2] DESOXY was discovered by Alexander Shulgin and published in his book PiHKAL . [2]

Contents

Use and effects

A typical dose is within the range of 40 to 120 mg orally and lasts 6 to 8 hours. [1] The effects of DESOXY vary significantly from mescaline, despite their chemical similarity. [1] Its effects included closed-eye imagery but no open-eye visuals. [1]

Interactions

Pharmacology

Pharmacodynamics

DESOXY acts as a serotonin 5-HT2 receptor agonist. [3]

Society and culture

United States

In 1970 the Controlled Substances Act placed mescaline into Schedule I in the United States. It is similarly controlled in other nations. Depending on whether or not it is intended for human consumption, 4-desoxymescaline could be considered an analogue of mescaline, under the Federal Analogue Act and similar bills in other countries, making it illegal to manufacture, buy, possess, or distribute without a DEA or related license. DESOXY is also an isomer of 2C-D which makes it a schedule 1 drug in the United States.

See also

References

  1. 1 2 3 4 5 Shulgin, Alexander; Ann Shulgin (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628.
  2. 1 2 3 Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. pp. 46–47. ISBN   978-0-9630096-3-0 . Retrieved 2 November 2024.
  3. ↑ Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun. 14 (1) 8221. Bibcode:2023NatCo..14.8221W. doi:10.1038/s41467-023-44016-1. PMC   10724237 . PMID   38102107.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.